Droplet Digital PCR for <i>BCR–ABL1</i> Monitoring in Diagnostic Routine: Ready to Start?

<i>BCR–ABL1</i> mRNA levels represent the key molecular marker for the evaluation of minimal residual disease (MRD) in chronic myeloid leukemia (CML) patients and real-time quantitative PCR (RT-qPCR) is currently the standard method to monitor it. In the era of tyrosine kinase inhibitors...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Maria Teresa Bochicchio, Jessica Petiti, Paola Berchialla, Barbara Izzo, Emilia Giugliano, Emanuela Ottaviani, Santa Errichiello, Giovanna Rege-Cambrin, Claudia Venturi, Luigiana Luciano, Filomena Daraio, Daniele Calistri, Gianantonio Rosti, Giuseppe Saglio, Giovanni Martinelli, Fabrizio Pane, Daniela Cilloni, Enrico M. Gottardi, Carmen Fava
Format:	article
Langue:	EN
Publié:	MDPI AG 2021
Sujets:	chronic myeloid leukemia ddPCR <i>BCR–ABL1</i> deep molecular response treatment-free remission Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/9821f3a48f02453b8ebd95e92daef6e3
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Droplet Digital PCR for <i>BCR–ABL1</i> Monitoring in Diagnostic Routine: Ready to Start?

Documents similaires